Scarica l'app Stockscreener
26.93
3.62%
0.94
Dopo l'orario di chiusura:
26.82
-0.11
-0.41%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
Beam Therapeutics Secures Standby License for Key Patents - TipRanks
Buyout Rumor: Will Alector Inc stock hit new highs in YEAR2025 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Volume Summary: What is Beam Therapeutics Incs debt to equity ratioJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - baoquankhu1.vn
Understanding Momentum Shifts in (BEAM) - Stock Traders Daily
Aug Reactions: What is Beam Therapeutics Incs debt to equity ratioJuly 2025 Fed Impact & Verified Technical Trade Signals - baoquankhu1.vn
FMR LLC's Strategic Acquisition of Beam Therapeutics Inc. Shares - GuruFocus
Beam Therapeutics Meets 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Beam Therapeutics (NASDAQ:BEAM) Downgraded by Wall Street Zen to Sell - MarketBeat
Top CRISPR Companies for 2026 and How to Invest - The Motley Fool
IQ EQ FUND MANAGEMENT IRELAND Ltd Buys 188,243 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics announces upcoming board member resignation - TipRanks
Bear Alert: Can Beam Therapeutics Inc. sustain its profitability2025 Stock Rankings & Safe Entry Point Identification - baoquankhu1.vn
Beam Therapeutics Inc. (BEAM) Stock Analysis: A 69% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Beam Therapeutics: A Critical Year for Clinical Validation - AD HOC NEWS
Y Intercept Hong Kong Ltd Takes Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Avoiding Lag: Real-Time Signals in (BEAM) Movement - Stock Traders Daily
Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933 - The Globe and Mail
Privium Fund Management B.V. Acquires Shares of 61,000 Beam Therapeutics Inc. $BEAM - MarketBeat
Wall Street Zen Upgrades Beam Therapeutics (NASDAQ:BEAM) to Hold - MarketBeat
Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM) - Finviz
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
ARK Investment Acquires 116K Shares of Beam Therapeutics (BEAM) - GuruFocus
Beam Therapeutics Inc. (BEAM) Stock Analysis: A Look at the 46.90% Potential Upside and Cutting-Edge Genetic Medicine Advancements - DirectorsTalk Interviews
Christine Bellon Sells 1,371 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Shares Down 7.6%Here's Why - MarketBeat
Sickle Cell Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics, Graphite Bio, Roche - Barchart.com
JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35 - 富途资讯
William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating - 富途资讯
Cathie Wood Sells Beam Therapeutics Stock, Buys WeRide and Tempus AI - Blockonomi
Cathie Wood Sells $5 Million Beam Therapeutics Stock, Buys WeRide and Tempus AI - CoinCentral
Campbell & CO Investment Adviser LLC Lowers Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Is Beam Therapeutics Inc forming a breakout pattern2025 Key Highlights & Free Community Consensus Stock Picks - baoquankhu1.vn
Beam soars 22% as FDA signs off on its ambitious gene-editing plan - MSN
Growth Report: Is Butterfly Network Inc Equity Warrant stock a buy or sellMarket Sentiment Summary & Advanced Technical Signal Analysis - baoquankhu1.vn
cathie wood’s ARK sells beam therapeutics stock, buys weride and tempus ai By Investing.com - Investing.com India
cathie wood’s ARK sells beam therapeutics stock, buys weride and tempus ai - Investing.com
Beam Therapeutics (NASDAQ:BEAM) Trading 11.1% HigherWhat's Next? - MarketBeat
Cathie Wood Dumps Beam Therapeutics, Loads Up on Netflix Stock - Blockonomi
Cathie Wood’s ARK ETFs Buy Netflix, Sell Beam Therapeutics in Latest Moves - CoinCentral
Beacon trial data makes Beam Therapeutics (BEAM) an attractive buy - MSN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: TransMedics Group (TMDX), Beam Therapeutics (BEAM) and Boston Scientific (BSX) - The Globe and Mail
Insider Sell: Bethany Cavanagh Sells Shares of Beam Therapeutics Inc (BEAM) - GuruFocus
Beam Therapeutics (BEAM) Receives Rating Update with Raised Pric - GuruFocus
Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway By Investing.com - Investing.com India
Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway - Investing.com Nigeria
Discipline and Rules-Based Execution in BEAM Response - Stock Traders Daily
Insider Selling: Beam Therapeutics (NASDAQ:BEAM) Insider Sells 18,629 Shares of Stock - MarketBeat
SG Americas Securities LLC Purchases 36,004 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
JPM26: Beam, Cabaletta, More Zero In on Regulatory Alignment After Tumultuous Year - BioSpace
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.1%Should You Sell? - MarketBeat
Earnings Report: Is Beam Therapeutics Inc a cyclical or defensive stock2025 EndofYear Setup & Accurate Intraday Trade Tips - baoquankhu1.vn
Aug Intraday: What is Rapid7 Incs 5 year growth outlookPortfolio Return Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Beam Therapeutics stock maintains Buy rating at H.C. Wainwright on FDA alignment - Investing.com Nigeria
Gene editing trials in sickle cell advance as Beam builds $1.1B cash - Stock Titan
Institution Moves: Will BHRPRD announce a stock splitPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
Sumitomo Mitsui Trust Group Inc. Has $117.24 Million Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
BEAM: Base editing programs advance toward approval, backed by strong data, funding, and scalable technology - TradingView — Track All Markets
BEAM: Predictable gene editing advances drive pivotal programs and commercial readiness into 2029 - TradingView
Buyback Watch: How does AHTPRI score in quality rankingsQuarterly Market Summary & Growth Focused Entry Point Reports - baoquankhu1.vn
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):